推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

CANCER BIOLOGY & THERAPY

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 CANCER BIOL THE最新评论:请问撤稿是直接给编辑写信还是系统里撤稿?需要等编辑部回信后再改投吗 (2022-06-10)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
出版社推荐:美国化学会ACS期刊一览IF 2.9,JCR Q2 神经系统基础研究期刊征稿中开放获取选刊时如何避雷?点击查看干货指南!
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


CANCER BIOLOGY & THERAPY期刊基本信息Hello,您是该期刊的第78951位访客


基本信息 登录收藏
期刊名字CANCER BIOLOGY & THERAPYCANCER BIOLOGY & THERAPY

CANCER BIOL THER
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
6.4
52人评分
我要评分

声誉
7.5

影响力
5.3

速度
6.9

期刊ISSN1538-4047
微信扫码收藏此期刊
E-ISSN1555-8576
2023-2024最新影响因子
(数据来源于搜索引擎)
4.4 点击查看影响因子趋势图
实时影响因子 截止2024年10月29日:3.587
2023-2024自引率0.00%点击查看自引率趋势图
五年影响因子4.4
JCI期刊引文指标 0.86
h-index 101
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
7.000.9140.688
学科分区排名百分位
大类:Medicine
小类:Oncology
Q194 / 404
大类:Medicine
小类:Pharmacology
Q290 / 313
大类:Medicine
小类:Cancer Research
Q282 / 230
大类:Medicine
小类:Molecular Medicine
Q265 / 178

期刊简介
Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.
期刊官方网站http://www.tandfonline.com/loi/kcbt20#.V4he8kz9cSQ
期刊投稿网址https://www.editorialmanager.com/CBT
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CANCER BIOLOGY & THERAPY的语言要求,还能让CANCER BIOLOGY & THERAPY编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CANCER BIOLOGY & THERAPY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇)
提交文稿
是否OA开放访问No

LetPub与Taylor & Francis签署APC支持服务战略合作协议,选择APC支持服务可享受:多样化支付选项,国税发票,加速发表,京东购物卡福利。了解详情>>>
通讯方式LANDES BIOSCIENCE, 1002 WEST AVENUE, 2ND FLOOR, AUSTIN, USA, TX, 78701
出版商Landes Bioscience
涉及的研究方向医学-肿瘤学
出版国家或地区UNITED STATES
出版语言English
出版周期Monthly
出版年份2002
年文章数 81点击查看年文章数趋势图
Gold OA文章占比79.27%
研究类文章占比:
文章 ÷(文章 + 综述)
93.83%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:2区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ286/322
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ298/322
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区4区2区
ONCOLOGY
肿瘤学
2区1区4区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区3区3区
ONCOLOGY
肿瘤学
2区1区4区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 2区3区3区
ONCOLOGY
肿瘤学
2区1区4区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1538-4047%5BISSN%5D
平均审稿速度网友分享经验:
平均2.3月
平均录用比例网友分享经验:
约50%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在CANCER BIOLOGY & THERAPY顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 CANCER BIOLOGY & THERAPY期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 CANCER BIOLOGY & THERAPY中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
CANCER BIOLOGY & THERAPY上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    Nature Reviews Clinical Oncology12799.40
    NATURE REVIEWS CANCER396111.90
    ANNALS OF ONCOLOGY21063.90
    CANCER CELL29555.20
    JOURNAL OF CLINICAL ONCOLOGY49441.20
    LANCET ONCOLOGY27462.10
    CANCER RESEARCH41116.10
    SEMINARS IN CANCER BIOLOGY13426.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6718.20
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE681284
    BIOMATERIALS569558
    BIOMEDICINE & PHARMACOTHERAPY555036
    Frontiers in Pharmacology518609
    Journal of Materials Chemistry B512175
    Frontiers in Immunology495781
    COMPUTERS IN BIOLOGY AND MEDICINE478106
    JOURNAL OF ETHNOPHARMACOLOGY469522
    COLLOIDS AND SURFACES B-BIOINTERFACES440405
    Frontiers in Oncology438941
  •  

    CANCER BIOLOGY & THERAPY CANCER BIOLOGY & THERAPY
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.

    Author: Sun Y1, Wang P2, Yang W1, Shan Y1, Zhang Q1, Wu H3.
    Journal: Cancer Biol Ther. 2019;20(6):729-739. doi: 10.1080/15384047.2018.1529121. Epub 2019 Mar 27.
        PubMed      DOI
    2.EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.

    Author: Lei T1, Zhu X2, Zhu K2, Jia F1, Li S1.
    Journal: Cancer Biol Ther. 2019 Mar 31:1-10. doi: 10.1080/15384047.2019.1595276. [Epub ahead of print]
        PubMed      DOI
    3.Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.

    Author: Zhu X1, Zhang Q2, Wang D1, Liu C1, Han B2, Yang JM3.
    Journal: Cancer Biol Ther. 2019 Mar 31:1-8. doi: 10.1080/15384047.2019.1595282. [Epub ahead of print]
        PubMed      DOI
    4.Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.

    Author: Wang D1, Qian G1, Wang J1, Wang T1, Zhang L1, Yang P1, Lin F1.
    Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1591675. [Epub ahead of print]
        PubMed      DOI
    5.The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.

    Author: Zhou Y1, Yin L2, Li H1, Liu LH1, Xiao T1.
    Journal: Cancer Biol Ther. 2019 Apr 12:1-8. doi: 10.1080/15384047.2019.1598766. [Epub ahead of print]
        PubMed      DOI
    6.A regulatory circuit of circ-MTO1/miR-17/QKI-5 inhibits the proliferation of lung adenocarcinoma.

    Author: Zhang B1, Chen M1, Jiang N1, Shi K1, Qian R1.
    Journal: Cancer Biol Ther. 2019 Apr 12:1-9. doi: 10.1080/15384047.2019.1598762. [Epub ahead of print]
        PubMed      DOI
    7.Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway.

    Author: Zhang C1, Bao C2, Zhang X2, Lin X2, Pan D1, Chen Y2.
    Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1599671. [Epub ahead of print]
        PubMed      DOI
    8.Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

    Author: Jing W1,2, Yan W1,3, Liu Y4, Li J1,3, Yu J1,3, Zhu H1,3.
    Journal: Cancer Biol Ther. 2019 Apr 14:1-6. doi: 10.1080/15384047.2019.1598760. [Epub ahead of print]
        PubMed      DOI
    9.MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway.

    Author: Liu T1, Guo J2, Zhang X1.
    Journal: Cancer Biol Ther. 2019 Apr 14:1-10. doi: 10.1080/15384047.2019.1591674. [Epub ahead of print]
        PubMed      DOI
    10.Serum metabolite profiling of familial adenomatous polyposis using ultra performance liquid chromatography and tandem mass spectrometry.

    Author: Sun L1, Kang Q2, Pan Y2, Li N2, Wang X2, He Y2, Wang H2, Yu D2, Xie H2, Yang L2, Lu Y3, Jin P2, Sheng J1.
    Journal: Cancer Biol Ther. 2019 Apr 14:1-12. doi: 10.1080/15384047.2019.1595277. [Epub ahead of print]
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    Energy Material Advances013.80
    Journal of High Energy Astrophysics119.70
    VIEW012.60
    HARVARD BUSINESS REVIEW01.40
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE1086.90
    ACM Transactions on Intelligent Systems and Technology469.30
    Journal of the American Nutrition Association02.50
    TRANSACTIONS OF TIANJIN UNIVERSITY012.50
    Machine Intelligence Research06.70
    Molecular Biomedicine06.30
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共7


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室